Access brought to you by: LOCKSS
Login
Primary End Point of the IMPROVE-IT Trial
IMPROVE-IT, Improved Reduction of Outcomes: Vytorin (Ezetimibe/Simvastatin) Efficacy International Trial.
Reproduced with permission from CP Cannon, MD.
Thank you for your interest in spreading the word on MD Conference Express.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.